Patterns of chronic and transient hyperkalaemia and clinically important outcomes in patients with chronic kidney disease

ABSTRACT Background Whether hyperkalaemia in CKD is chronic or transient, and whether this has different outcome implications, is not known. Methods This was an observational study of adults with CKD G3–5 from Stockholm, Sweden 2006–11. We examined individual trajectories of potassium from all measurements obtained through routine outpatient care. For each month of follow-up, we created a rolling assessment of the proportion of time in which potassium was abnormal during the previous 12 months. We defined patterns of hyperkalaemia as transient (≤50% of time during the previous year with potassium >5.0 mmol/L) and chronic (>50% of time with potassium >5.0 mmol/L), and examined whether previous hyperkalaemia pattern offers additional predictive value beyond that provided by the most recent (current) potassium value. Results We included 36 511 participants (56% women) with CKD G3–5 and median estimated glomerular filtration rate 46 mL/min/1.73 m2. Transient and chronic hyperkalaemia, respectively, were observed in 15% and 4% of patients with CKD G3a, and in 50% and 17% of patients with CKD G5. In fully adjusted models, transient (hazard ratio 1.36, 95% confidence interval 1.29–1.46) or chronic (1.16, 1.04–1.32) hyperkalaemia patterns, but not current hyperkalaemia, were associated with major adverse cardiovascular events (MACE), compared with normokalaemia. Transient hyperkalaemia (1.43, 1.35–1.52) and current potassium values, but not chronic hyperkalaemia, were associated with the risk of death. Conclusions Between 4% and 17% of patients with CKD G3–5 develop chronic hyperkalaemia. In general, hyperkalaemia predicted MACE and death; however, the lack of effect of current potassium on MACE when adjusted for the previous pattern, and the stronger effects on death than on MACE, lead us to question whether hyperkalaemia is causal in these relationships.

[1]  K. Kalantar-Zadeh,et al.  Potassium Trajectories prior to Dialysis and Mortality following Dialysis Initiation in Patients with Advanced CKD , 2021, Nephron.

[2]  J. Carrero,et al.  Clinical Management of Hyperkalemia. , 2020, Mayo Clinic proceedings.

[3]  J. Carrero,et al.  Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. , 2019, Kidney international.

[4]  J. Coresh,et al.  Dyskalemia, its patterns, and prognosis among patients with incident heart failure: A nationwide study of US veterans , 2019, PloS one.

[5]  A. Sjölander,et al.  Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  A. Garg,et al.  Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age. , 2019, JAMA internal medicine.

[7]  L. Pedersen,et al.  Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients — A population-based cohort study , 2019, PloS one.

[8]  H. Heerspink,et al.  Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care , 2018, Journal of clinical medicine.

[9]  H. Sørensen,et al.  Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes—a Danish population-based cohort study , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  L. Lund,et al.  Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  A. Levin,et al.  Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis , 2018, European heart journal.

[12]  E. Nilsson,et al.  Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. , 2017, International journal of cardiology.

[13]  M. Metra,et al.  Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality , 2017, Circulation.

[14]  J. Ludvigsson,et al.  The Swedish cause of death register , 2017, European Journal of Epidemiology.

[15]  J. Coresh,et al.  Prevalence and recognition of chronic kidney disease in Stockholm healthcare. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  K. Michaëlsson,et al.  Registers of the Swedish total population and their use in medical research , 2016, European Journal of Epidemiology.

[17]  S. Brunelli,et al.  Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[18]  Marie Evans,et al.  The Stockholm CREAtinine Measurements (SCREAM) project: protocol overview and regional representativeness , 2015, Clinical kidney journal.

[19]  S. Navaneethan,et al.  Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease , 2015, American Journal of Nephrology.

[20]  S. Yusuf,et al.  The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial , 2014, European journal of preventive cardiology.

[21]  Chapter 1: Definition and classification of CKD , 2012, Kidney International Supplements.

[22]  J. Ludvigsson,et al.  External review and validation of the Swedish national inpatient register , 2011, BMC public health.

[23]  A. Collins,et al.  Hemoglobin variability and mortality: confounding by disease severity. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  B. Pitt,et al.  Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[25]  M. Zhan,et al.  The frequency of hyperkalemia and its significance in chronic kidney disease. , 2009, Archives of internal medicine.

[26]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[27]  Rajiv Saran,et al.  Patient awareness of chronic kidney disease: trends and predictors. , 2008, Archives of internal medicine.

[28]  M. Joffe,et al.  Hemoglobin variability and mortality in ESRD. , 2007, Journal of the American Society of Nephrology : JASN.

[29]  Anders Sundström,et al.  The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months , 2007, Pharmacoepidemiology and drug safety.

[30]  P. Hyltoft Petersen,et al.  The Nordic Reference Interval Project 2000: recommended reference intervals for 25 common biochemical properties , 2004, Scandinavian journal of clinical and laboratory investigation.

[31]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[32]  A. B. Hill The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.

[33]  J. Hazard,et al.  [Correction of electrocardiographic signs of hyperpotassemia by calcium chloride]. , 1952, Comptes rendus des seances de la Societe de biologie et de ses filiales.

[34]  Vega Solís,et al.  Precisión de la función renal en los adultos mayores mediante las fórmulas Cockcroft-Gault, MDRD (Modification of Diet in Renal Disease) y CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration ) , 2017 .